Roche Signals It Is Too Soon to Know if AI Improves Trial Success Rates — Market Talk

Roche Holding's research and early development is becoming more productive thanks to the integration of AI into its workflows, but it is too soon to know if the technology improves a drug candidate's chances in a clinical trial, J.P. Morgan analysts say in a research note. The Swiss drugmaker said…